Graph Therapeutics, a cutting-edge biotechnology startup, has successfully raised $3.25 million in pre-seed funding to accelerate the development of its innovative AI-driven platform for drug discovery. This investment marks a significant milestone in the company’s mission to tackle complex inflammatory diseases using advanced artificial intelligence and machine learning techniques.
This funding round was spearheaded by leading investors, including Squareone and Merantix Capital, alongside NAVEC Investment Management and strategic angel investors. Among these contributors is Mehdi Ghissas
Leave a Reply